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Background: Localized early-stage extra-nodal marginal zone lymphoma (MZL) presents with heterogeneous organ involve-
ment and is treated with various modalities, including resection, radiotherapy, and systemic therapy. We report the long-term
outcome of a large cohort of extra-nodal MZL and assess the impact of patient and disease characteristics, organ site, and
treatment strategy on disease control and survival.
Patients and methods: We identified 487 consecutive patients with stage IE or IIE MZL referred between 1992 and 2012 to
Memorial Sloan Kettering Cancer Center. Pathology was reviewed by hematopathologists at our institution. Patient and
disease factors as well as treatment types were analyzed for association with relapse-free survival, overall survival, and cumula-
tive incidence of relapse.
Results: Median follow-up after treatment was 4.7 years. Five-year relapse-free survival and overall survival were 60% and 89%,
respectively. Cumulative incidence of disease-specific death at 5 years was 1.3%. Radiotherapy alone was the initial treatment
in 50% of patients, followed by surgical resection (30%), observation (8%), immunotherapy (4%), and chemotherapy (2%). Initial
treatment type, primary disease site, and number of involved sites were significant factors in multivariable analysis of relapse
(all P< 0.05). When compared with stomach, MZL originating in other disease sites (HR> 2.0, P 0.001), except for thyroid,
had higher risk of relapse. Strategies such as antibiotics or topical therapies were associated with higher risk of relapse when
compared with radiation therapy (P< 0.001). Crude rate of transformation to pathologically confirmed large-cell lymphoma
was 2% (11 patients).
Conclusion: Overall and cause-specific survival are high in early-stage extra-nodal MZL. Curative-intent treatment led to fewer
relapses and reduced the need for salvage. Stomach cases had lower risk of relapse than other anatomic primary sites. This
study supports the use of local therapies to treat stage IE and IIE MZL.
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Introduction
Extra-nodal mucosa-associated lymphoid tissue (MALT) lymph-
oma represents 70% of marginal zone B-cell lymphomas
(MZL) while splenic and nodal sites make up the remaining 30%
of cases [1]. Extra-nodal MZL presents in a variety of organs,
such as the stomach, orbital adnexa, salivary glands, and lungs,
among other sites. Extra-nodal MZL has been linked with two
main bacterial infections: Helicobacter pylori infection in gastric
MZL and Chlamydia psittaci in orbital tissues, with geographic
variation in frequencies [1]. Treatment of H. pylori leads to
VC The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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regression of lymphoma in many gastric cases. In other sites,
chronic autoimmune or inflammatory conditions are associated
with development of MZL, such as Sjogren syndrome in salivary
glands and Hashimoto thyroiditis in the thyroid.
Extra-nodal MZL is typically diagnosed at an early, localized
stage in 60%–80% of cases [2, 3], making local treatments the
preferred initial treatment approach. However, the treatment
regimens used in practice are variable, with some patients receiv-
ing systemic therapy despite staging workup that confirms the
localized nature of disease. Recent analysis of the National
Cancer Database shows a survival detriment to omission of radio-
therapy (RT) in early stage MZL [4]. A Surveillance,
Epidemiology and End Results (SEER)-Medicare database ana-
lysis of stage IE gastric MALT lymphoma showed that RT was
associated with lower risk of lymphoma-related death than
chemotherapy [5]. The available studies on this disease have not
consistently assessed the response to primary therapies, mostly
due to small patient numbers, a lack of homogenous patient co-
horts and variable follow-up strategy [3, 4, 6–12]. Furthermore,
these studies find conflicting prognostic factors for disease re-
lapse and survival.
In this study, we describe the response and long-term outcome
of early-stage disease following various initial therapies. We also
aim to find prognostic factors for relapse and survival.
Materials and methods
Patient selection
We carried out an IRB-approved retrospective analysis of the medical re-
cords of 487 consecutive patients treated at Memorial Sloan Kettering
Cancer Center who had biopsy-proven stage I or II extra-nodal MZL
diagnosed between January 1992 and September 2012. All patients had
pathologic confirmation of MZL diagnosis by aMSKCC hematopatholo-
gist. We collected information on clinical features, stage, diagnostic stud-
ies, performance status, International Prognostic Index [13] score,
treatments received, follow-up examinations, relapses or progression of
disease (PD), and salvage therapies for recurrences.
Initial workup
Staging workup followed institutional standards for the disease site as
well as NCCN guidelines. Work-up included an appropriate imaging
study [positron emission tomography (PET) scan, computed tomog-
raphy (CT), or magnetic resonance imaging (MRI)] as well as complete
blood count and basic metabolic panel. All patients with gastric MZL
were diagnosed by esophagogastroduodenoscopy (EGD) inspection and
biopsy. Bone-marrow biopsy was carried out at physician discretion.
Treatment
Extra-nodal MZLs were treated with a relatively homogenous therapeutic
strategy. Treatment of early-stage extra-nodal MZL at our institution
constitutes primarily either radiotherapy or surgical resection. A cohort
of patients treated only with RT has been previously published [15].
Some patients are treated at physician discretion with systemic therapies
including cytotoxic chemotherapy or targeted immunotherapies, in par-
ticular rituximab. Gastric MZL patients are referred for RT if they have
H. pylori-independent disease (biopsy does not identify H. pylori) or fail
antibiotic therapy forH. pylori eradication based on repeat gastric biopsy.
Based on the clinical setting, such as skin MZL or patients who wish to
delay treatment, a minority of patients are initially managed with antibi-
otics, topical steroids, or observation (active surveillance approach).
Follow-up
Patients were typically seen 1-4months after completing treatment of ini-
tial response and toxicity assessment. Imaging studies were used to assess
response for most sites, with the exception of skin and orbit sites, where
principally clinical examination was used. For gastric MZL, EGD with bi-
opsy was customarily carried out every 4-6 months for the first 2-3 years,
after which annual EGDwas carried out.
Radiographic response was determined according to the International
Working Group response criteria [14] at time of first follow-up imaging
study; in some cases, we retrospectively ascertained clinical or radio-
graphic response. Responses were categorized as one of the following:
complete response (CR), complete response uncertain (CRu), partial re-
sponse (PR), stable disease (SD), and PD.
For all patients receiving treatment, a progression or relapse event
during follow-up was classified as any measurable, biopsy-proven, or
visible increase in existing disease; relapse in initial site after initial CR;
or the development of an entirely new site of MZL. For gastric MZL,
biopsy-proven recurrence was required to determine relapse. Disease
that transformed to large cell lymphoma was also considered a progres-
sion event.
Treatment technique
Patients who received RT were treated with either involved field RT
(IFRT) or involved site RT (ISRT) without intentional prophylactic treat-
ment of regional nodes unless the nodal drainage fell within the involved
field, as previously reported [10]. Surgical resection involved removal of
all visible disease on imaging or clinical examination.
Statistical analysis
Endpoints of our study were overall survival (OS), relapse-free survival
(RFS), disease-specific death rate, relapse rate, and in-field failure rate
after RT. Follow-up began from treatment start date for all endpoints ex-
cept in-field failure. For OS, patients were followed until date of death or
last contact, if still alive; for disease-specific death, death due to causes
unrelated to MZL was considered a competing risk event. For RFS, pa-
tients were followed until the date of progression, relapse in previous or
new site, death, or last follow-up; for the relapse endpoint, death without
relapse was a competing risk event. For in-field failure after RT, which
included patients that received RT any time after diagnosis, patients were
followed from end of RT until progression or recurrence within the irra-
diated site and death without in-field failure was a competing risk event.
Median OS and RFS were estimated by Kaplan–Meier methods.
Cumulative incidence rates of all other endpoints were estimated by com-
peting risk methods.
We further estimated the cumulative incidence of first relapse at spe-
cific sites (local, regional, distant) after CR or CRu to initial treatment.
Patients were followed from the date of CR/CRu determination until first
relapse. Death without relapse was considered a competing risk event.
To identify prognostic factors associated with OS and relapse, we car-
ried out multivariable analysis (MVA) using Cox regression and compet-
ing risk regression. For each endpoint, factors with a P< 0.2 by
univariate analysis (UVA) were assessed by MVA and backwards selec-
tion was used to reduce the model and retain only factors with P< 0.05.
To evaluate the association of relapse with OS, relapse was analyzed as a
time-dependent variable to account for biases related to different lengths
of waiting time between diagnosis and relapse. Age differences by disease
site were assessed with analysis of variance. Competing risks analysis was
carried out using package cmprsk in R version 2.11.1 (The R Foundation
for Statistical Computing). All other statistical analyses were carried out
in SAS version 9.2 (SAS Institute, Cary, NC).
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Results
Patient characteristics
Median follow-up was 4.7 years (range 0.01-21.3 years) overall
and 4.6 years among 415 survivors (range 0.01-21 years). Median
age at diagnosis was 60 years (range 9–92). A 57% of patients
were female (Table 1). Most patients (89%) had Ann Arbor stage
IE disease. Primary site of disease was the stomach in 32%, orbit
in 14%, lung in 12%, skin in 13%, parotid in 5%, thyroid in 2%,
and other in 22% (Table 1; supplementary Figure S1, available at
Annals of Oncology online). IPI score was zero or one (low risk) in
95% and two (low-intermediate risk) in 5%; 4% of patients had
B-symptoms at diagnosis. Age differed significantly between the
major categories of primary disease site (supplementary Table S1,
available at Annals of Oncology online), with parotid and skin
MZL presenting at younger ages.
For staging workup, 58% of patients had PET scan, 87% had
CT scan, and 49% had both PET and CT. EGD was carried out in
41% of patients and MRI was done in 18%. Bone-marrow biopsy
was carried out and was negative in 54% of patients; 45% of pa-
tients did not undergo bone marrow sampling.
Forty-five patients (9%) had a prior autoimmune disorder diag-
nosis, including Sjogren’s disease in 20 patients, Hashimoto’s thy-
roiditis in nine, rheumatoid arthritis in 11, systemic lupus
erythematosus in three, and inflammatory bowel disease in two pa-
tients. Helicobacter pylori infection was diagnosed in 44 patients
with gastric MZL. The majority of H. pylori-positive gastric pa-
tients (84%) received antibiotic therapy. Non-gastric patients were
not treated with antibiotics againstH. pylori. Patients were referred
for radiotherapy if found to have persistent gastricMZL after com-
pletion of antibiotics and repeat endoscopy with biopsy.
Initial treatments
Treatments started shortly after diagnosis with a median interval
of 1.5 months. Radiotherapy was the most common initial treat-
ment, given in 50% of patients (Tables 1 and 2). Surgical resec-
tion was the second most common therapy (30%), followed by
observation (8%), other treatments (6%: includes oral antibiotics
in 19 patients and topical corticosteroids in five), immunother-
apy (4%), and systemic chemotherapy (2%). Observation was the
initial strategy in 39 patients representing various disease sites,
with the most common site being skin (44%) followed by orbit
(18%). Immunotherapy consisted of rituximab in 17 of 19 pa-
tients. Patients who received non-local therapies were not more
likely to have B-symptoms, nor did they have higher IPI score.
See supplementary results, available at Annals of Oncology online
for details about systemic therapy and RT, including toxicity.
Response rates
All 144 patients treated with surgery had complete resections and
therefore achieved CR. Among the 274 total patients receiving
curative initial treatments (RT, chemotherapy, or immunother-
apy), 82% achieved CR, 4% achieved CRu, 6% achieved PR, 4%
had stable disease, and 1% experienced PD during treatment.
Response was not recorded in 2% of patients. Among the RT-
only group, 89% achieved CR, 5% had CRu, 3% had PR, 1% had
SD, 1 patient had PD, and 2% had unknown response.
Overall survival
Seventy-two patients died during the follow-up period. Median
OS was 15 years (95% CI 14.4–not reached). Five-year OS was
89% (95% CI 85%–92%), and 10-year OS was 73% (95% CI
65%–79%) (Figure 1A). Cause of death was MZL in six patients,
other cause in 44 patients, and uncertain in 22 patients.
Table 1. Characteristics of early stage patients
Characteristic N 5 487
Age Median (range) 60 (9–92)
Gender
Female 277 (57%)
Male 210 (43%)
Stage
I 434 (89%)
II 53 (11%)
Primary site at diagnosis
Stomach 155 (32%)
Orbit 68 (14%)
Lung 60 (12%)
Skin 61 (13%)
Head and neck 26 (5%)
Thyroid 9 (2%)
Other 108 (22%)
IPI risk group
Unknown 2 (0%)
Low risk (0–1 points) 461 (95%)
Low-intermediate risk (2 points) 24 (5%)
B-symptoms at diagnosis
Not present 463 (95%)
Present 18 (4%)
N/A 6 (1%)
Initial treatment type
Surgery 144 (30%)
Chemotherapy 9 (2%)
Radiation therapy 244 (50%)
Chemotherapy and RTa 2 (0%)
Immunotherapy 19 (4%)
Observation 39 (8%)
Other 30 (6%)
Sites at diagnosis
>1 site 37 (8%)
1 site 450 (92%)
Bone marrow biopsy
Not done or N/A 222 (46%)
Negative 265 (54%)
Among patients receiving RT as initial treatment (N¼ 246)b
RT dose
<3000 42 (17%)
3000 157 (64%)
>3000 37 (15%)
Unknown dose 10 (4%)
Percentages may not add up to 100 due to rounding.
aGrouped with RT for analysis.
bIncludes ChemoRT as initial treatment.
IPI, International Prognostic Index; RT, radiotherapy.
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The 5- and 10-year cumulative incidences of disease-specific
death are 1.3% (95% CI 0.02%––2.6%) and 1.8% (95% CI
0.2%––3.3%), respectively (Figure 1B). Non-lymphoma causes
of death included second primary solid tumor malignancies (not
associated with treatment) in 22 patients, second primary hema-
tologic malignancies in 6 patients, medical causes including
pneumonia in 6 patients, and car accident in one. Eight of the 22
patients with uncertain cause of death had experienced relapse at
some time before death, including two with transformed disease;
all eight were treated for their relapse. The median age at death
for these patients was 73 years.
Relapses and progression
One-hundred ninety-five patients experienced relapse or death
during the follow-up period, of which 151 patients relapsed (28
of whom died subsequently), and 44 patients died without a re-
lapse. Median RFS was 8.1 years (95% CI 6.3–9.7 years). Five-
year RFS was 60% (95% CI 55%––65%), and 10-year RFS was
42% (95% CI 35%––49%) (Figure 2A). For details of relapse lo-
cations and salvage therapies, refer to supplementary results and
Tables S3–S5, and Figure S2, available at Annals of Oncology
online.
The 5-year cumulative incidence of relapse for all patients was
33% (95% CI 28%–38%), with a 10-year incidence of 42% (95%
CI 36%–48%) (Figure 2B). Patients who experienced progression
or relapse during the follow-up period had higher risk of death
that was borderline significant (HR 1.60, P¼ 0.06).
In both UVA and MVA for relapse, primary disease site, initial
treatment type, and number of sites at diagnosis were signifi-
cantly associated with relapse (Table 3; Figure 2C). Among treat-
ment types, only “other” treatments, such as topical therapies or
antibiotics, were significantly associated with a greater risk of re-
lapse than RT (HR 8.37, P< 0.001).
Among the 294 patients treated with RT either upfront or for a
relapse, 11 experienced failures within the radiation field. The 5-
and 10-year cumulative incidences of in-field failure after RT
were 2.4% (95% CI 0.5%–4%) and 4.7% (95% CI 0.8%–8.7%),
respectively.
Eleven patients (2%) experienced transformation of MZL to
pathologically confirmed large-cell lymphoma. Initial sites of dis-
ease were stomach (n¼ 5), orbit (3), parotid (2), and breast (1).
Of these, two died of disease. Transformation occurred at the pri-
mary disease site in three patients, and in a regional or distant site
in eight patients.
Discussion
We present, to our knowledge, the largest report of early-stage
extra-nodal marginal zone lymphoma treatment and outcomes
in the literature. With a median follow-up of almost 5 years, our
study presents a comprehensive picture of the disease course of
extra-nodal MZL. Our study confirms that extra-nodal MZL dis-
ease control is excellent following local or systemic therapies and
disease-specific death is rare. For patients who achieve CR to
treatment, local relapse is uncommon; when relapse does occur,
as is the case in one-third of patients, the relapsed disease is al-
most always a non-transformed MZL emerging in an extra-nodal
site and can be treated successfully in the relapsed setting.
An important finding of our data is that, despite the ability of
systemic chemotherapy or rituximab to treat disseminated
microscopic disease, patients treated with these modalities were
not less likely to relapse. Given these results, we prefer to avoid
the toxicities of systemic therapy, and instead offer all patients
local therapy for this disease. We reserve systemic therapy for the
few patients who relapse and require a systemic approach. The
low radiation doses required for CR are associated with few ser-
ious complications [15].
We identify several factors associated with risk of relapse in
early-stage extra-nodal MZL, including primary disease site and
initial treatment type. Compared with gastric primaries, patients
Table 2. Initial treatment types for each major MZL disease site
Initial treatment Stomach Orbit Lung Skin Parotid Thyroid Other
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Radiation therapy 122 (79) 44 (65) 1 (2) 19 (31) 7 (27) 5 (56) 48 (44)
Surgery 4 (3) 10 (15) 54 (90) 18 (30) 16 (62) 4 (44) 38 (35)
Chemotherapy 3 (2) 0 1 (2) 1 (2) 0 0 4 (4)
Immunotherapy 6 (4) 3 (4) 2 (3) 1 (2) 1 (4) 0 6 (6)
Observation 2 (1) 7 (10) 2 (3) 17 (28) 1 (4) 0 10 (9)
Other 18 (12) 4 (6) 0 5 (8) 1 (4) 0 2 (2)
Percentages may not add up to 100 due to rounding.
Overall survivalA B Cumulative incidence of
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Figure 1. (A) Overall survival. (B) Cumulative incidence of disease-speciﬁc deaths.
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with orbit, lung, skin, parotid, and other disease sites are signifi-
cantly more likely to relapse or progress. These sites tend to repre-
sent (i) paired organs such as orbit or parotid, and (ii) organs where
only the involved site of disease, and not the whole organ, is locally
treated—such as the lung and skin. In contrast, RT for stomach
MZL involves treatment of the entire organ. This variation in treat-
ment extent for different disease sites may explain higher relapse
rates between stomach and other sites. Our finding confirms similar
results from previous smaller studies [4, 12, 16–18]. The association
of certain organ sites with higher risk of relapse may support closer
follow-up for those patients, with special attention to the remainder
of the involved organ or to its contralateral, paired structure.
We find that, compared with RT, patients receiving “other”
treatments, including antibiotics and corticosteroids, were signifi-
cantly more likely to experience relapse while patients undergoing
surgery were not. Gastric, skin, or orbit sites are more likely to re-
ceive “other” therapies. Because these treatments do not address
the entire organ, patients will more likely have partial response and
Relapse-free survivalA B CCumulative incidence of relapse/progression Cumulative incidence of
relapse by primary disease site
N =483 (195 RFS events)
N =483 (151 events)
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Figure 2. (A) Relapse-free survival. (B) Cumulative incidence of relapse for all patients. (C) Cumulative incidence of relapse by primary disease site.
Table 3. Competing risk regression analysis for association of factors with relapse/progression (N5 483)a
Characteristic Strata Univariate Multivariable
HR (95%CI) P-value HR (95%CI) P-value
Age (per 10 years) 1.01 (0.89, 1.15) 0.87
Gender Female 1.0 0.76
Male 1.05 (0.76, 1.45)
Stage I 1.0 0.06
II 1.5 (0.99, 2.29)
Primary site at diagnosis Stomach 1.0 <0.001 1.0 <.001
Orbit 1.9 (1.13, 3.2) 2.01 (1.07, 3.78)
Lung 1.81 (1.03, 3.17) 3.16 (1.5, 6.66)
Skin 2.73 (1.6, 4.65) 2.99 (1.67, 5.35)
H&N 2.6 (1.34, 5.05) 3.8 (1.92, 7.54)
Thyroid 0.8 (0.22, 2.93) 1.23 (0.34, 4.41)
Other 1.91 (1.2, 3.06) 2.5 (1.51, 4.14)
IPI risk group Low (0–1 points) 1.0 0.26
Low-intermediate risk (2 points) 1.53 (0.73, 3.18)
B-symptomsa Not present at diagnosis 1.0 0.88
Present 1.08 (0.4, 2.91)
Initial treatment RT or ChemoRT 1.0 <0.001 1.0 <.001
Surgery 1.22 (0.83, 1.80) 0.69 (0.42, 1.14)
Chemo or immunotherapy 2.27 (1.19, 4.31) 1.5 (0.73, 3.09)
Observation 2.03 (1.19, 3.49) 1.24 (0.69, 2.24)
Other 8.27 (4.07, 17) 8.37 (4.39, 15.94)
No. sites at diagnosis >1 site 1.0 0.007 1.0 0.04
1 site 0.54 (0.34, 0.84) 0.58 (0.35, 0.97)
Bone marrow biopsy carried out No 1.0 0.09
Yes 0.76 (0.55, 1.04)
Variables with P-value<0.2 were selected for multivariable analysis and only variables with P-value< 0.05 were retained in the ﬁnal model.
aUnknown relapse status not included.
HR, hazard ratio; IPI, International Prognostic Index, RT, radiotherapy.
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eventual relapse. Patients who were observed were highly selected,
and likely had minimal residual disease burden after biopsy before
embarking on “observation only” approach.
Recent analyses of population databases have identified improved
outcomes in patients receiving RT as initial treatment of an early
stage extra-nodal MZL. Ling et al. identified over 22 000 patients in
the NCDB with stage I-II extra-nodal and nodal MZL from 1998 to
2012 [4]. They found that RT utilization had decreased over time
with a corresponding increase in systemic therapy. Propensity-score
adjusted survival analysis found that RT was independently associ-
ated with improved OS (Hazard ratio 0.75). An analysis of 1134
cases of stage IE gastric MZL from the SEER-Medicare database
found that RT was associated with a better cause-specific survival
comparedwith those treated with chemotherapy [5].
Other groups have reported excellent outcomes of early-stage
extra-nodal MZL that are further supported by our study. A multi-
center report [19] from the International Extra-nodal Lymphoma
StudyGroup (IELSG) reported on 102 patients receiving RT for gas-
tric MZL. Ten-year freedom from treatment failure and overall sur-
vival were 88% and 70%, respectively. Princess Margaret Hospital
investigators identified 192 patients with stage IE-IIE MZL treated
with RT, 23 of whom also received chemotherapy [6, 11]. Ten-year
RFS was 68% and 10-year cause-specific survival was 98%. Thyroid
and stomach sites had>90% 10-year recurrence-free rates. A pro-
spective phase II trial of RT in stage IEA MZL showed 3-year OS of
100% and local control of 97% [7]. Lastly, a study of stage IE orbital
MZL show>95% local control following RT [20]; 6 patients had a
contralateral orbital relapse andwere salvagedwith RT.
The limitation of our study is its retrospective nature. The nature
of treatments at a tertiary referral center such as ours does raise the
possibility of referral biases, whichmay explain the high number of
patients who received radiotherapy as primary treatment of gastric
MZL. Similarly, very few patients with gastric disease were treated
with surgery. Given the lack of a prospective study, our retrospect-
ive study presents a clear picture of the natural history of various
treatment strategies for early-stage extra-nodal MZL, one that can
inform treatment paradigms for future patients.
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